Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aids : Effectiveness of antiretroviral therapy demonstrated in Africa

28.06.2002


Tritherapies using antiretroviral drugs have proved their worth in industrialized countries in the fight against Aids. However, in Sub-Saharan Africa, where 70 % of people infected with HIV live, access to such treatments is extremely limited. High cost, complicated procedures, combined with inadequate infrastructures for following up patients or capable of delivering medicines regularly partly explain this situation. Moreover, efficacy of antiretroviral agents might not be the same for some HIV strains present in Africa. And not enough is yet known about the response to therapy (viral resistance, adverse effects and so on), notably in patients in advanced stages of immune deficiency. These factors are considered as obstacles to mounting concerted therapy programmes in Africa. For some government authorities they provide the arguments for concentrating control campaigns solely on prevention with no involvement of antiretroviral drugs.



Since 1998 the Senegalese government has been developing a programme facilitating access to Aids treatments (1). Within this, an assessment programme, coordinated by the IRD and the Senegal National Committee for Aids Control, and financed by the Agence nationale de recherches sur le sida (ANRS), has been deployed aiming to determine the effectiveness, the tolerance, the acceptability and feasibility of the standard form of antiretroviral therapy. This study was conducted in a cohort of 58 patients aged between 16 and 56 years, having high viral load and low CD4 cell count. Most of them (86.2%) had developed the disease before the start of the antiretroviral therapy. All received a combination treatment of two nucleoside reverse transcriptase inhibitors plus one protease inhibitor (2) The drugs were taken in three doses per day, just as in the industrialized countries. A sociological survey was done in parallel which assessed patients’ ability to contribute to part of the cost of the treatment depending on their financial resources. The rest would be subsidized by the programme.

At the end of the 18 month study, the results were comparable with those obtained in the countries of the North. Most patients (87.9 %) regularly followed the course of treatment over the whole period monitored. Also, contrary to prior assumptions, financial difficulties did not hinder adherence to the therapy. Furthermore, the same therapeutic efficacy was observed here as in the industrialized countries. After a year and a half of treatment the viral load was almost undetectable (below 500 copies/ml) in 59.3 % of cases and the CD4 cell count had risen markedly (about 180/mm3). Tolerance to antiretroviral medicines was generally good, adverse effects observed being only mild. Only two cases of viral resistance to the drugs were found.


This study gives proof that the therapeutic strategies developed in the industrialized countries can also be applied in Africa. The Senegalese initiative shows that this tritherapy method proves to be effective for most patients, even if their immunity deficiency is severe before embarking on antiretroviral treatments - and although many different strains of HIV-1 are circulating. It must be emphasized also that, contrary to results of several other studies conducted in Africa, viral resistance was rare. The researchers consider that the quality of follow-up of patients under the therapy regimens, attained by involving social workers and the regularity of medicine supply, contributed to the effectiveness. Judging by the excellent results obtained during this pilot phase, it now remains to ascertain that antiretroviral therapy maintains its efficacy over the long term and on a larger scale.

(1) Senegal, which launched its HAART in 1998, was among the first African countries, along with the Ivory Coast and Uganda, to set up a nation-wide programme to facilitate access to treatment for Aids.

(2) These antiretroviral drugs are active against two HIV targets : reverse transcriptase and protease. Both are enzymes. The first enables the viral RNA to transform into DNA so it can then become integrated with the DNA of the cell it infects. Protease builds up the constituent elements of the HIV, before it is released from the cell to spread further.


Marie-Lise Sabrie | alfa

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-Ever 3D Printed Excavator Project Advances Large-Scale Additive Manufacturing R&D

Heavy construction machinery is the focus of Oak Ridge National Laboratory’s latest advance in additive manufacturing research. With industry partners and university students, ORNL researchers are designing and producing the world’s first 3D printed excavator, a prototype that will leverage large-scale AM technologies and explore the feasibility of printing with metal alloys.

Increasing the size and speed of metal-based 3D printing techniques, using low-cost alloys like steel and aluminum, could create new industrial applications...

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Paper – Panacea Green Infrastructure?

30.09.2016 | Event News

HLF: From an experiment to an establishment

29.09.2016 | Event News

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

 
Latest News

First-Ever 3D Printed Excavator Project Advances Large-Scale Additive Manufacturing R&D

30.09.2016 | Materials Sciences

New Technique for Finding Weakness in Earth’s Crust

30.09.2016 | Earth Sciences

Cells migrate collectively by intermittent bursts of activity

30.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>